| INTRODUCTION
For many decades, stage IV lung cancer has been considered as a terminal disease. Recent improvements in therapies led to better prognosis and stage IV lung cancer is now considered a progressing illness. Recent American studies showed that 69% of 710 patients with incurable lung cancer and 81% of 483 patients with colorectal cancer who received palliative chemotherapy were unaware that the treatment was not curative (Brown Johnson, Brodsky & Cataldo, 2014; Temel, Greer & Muzikansky, 2010; Weeks, Catalono & Cronin, 2012) . The attitude towards patients' awareness of cancer diagnosis had shifted over time from non-disclosure to disclosure by the physician (Kazdaglis et al., 2010; Muthu, Symonds & Sunder, 2004; Shahidi, 2010; Yun, Lee & Kim, 2004) .
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. A systematic review showed that patients with lung cancer reported high psychological stress, depression, fatigue and sleep disturbance after cancer diagnosis (Walker, Sawhney & Hansen, 2013) . The most common fear related to patient awareness that they are terminally ill is that it will cause emotional distress and take away their hope (Kazdaglis et al., 2010) . Experts worldwide differ on whether patients who are terminally ill should be fully aware that they are dying (Kallergis, 2011) .
Preliminary results showed that patients with lung cancer are more vulnerable to psychosocial morbidity and high levels of distress than patients with other cancers (Brown Johnson et al., 2014) .
Studies have shown preference for erlotinib over chemotherapy as first-line therapy in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients (Zhou, Wu & Chen, 2015) . In China, cultural, social and legal factors play a fundamental role in not giving full disclosure of disease status to patients with cancer (Akechi, Okuyama & Andakizuki, 2006; Kerry & Hui, 2000; Pang, 1999) . Indeed, by law, the family is first disclosed the disease status and decides if the patient has to be aware of the exact disease status. Therefore, in China, most patients using only oral pills at home are usually not aware of their cancer diagnosis and prognosis.
No data are currently available about the impact of disease awareness on distress and quality of life (QoL) of patients with lung cancer treated with erlotinib. Therefore, this study aimed to examine whether the disclosure of cancer diagnosis and prognosis to patients with stage IV lung cancer with EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) treated with first-line erlotinib vary with baseline psychological distress and QoL.
| METHODS

| Participants
This was a retrospective study that was conducted at the During the 12-week follow-up, patients were excluded from the analyses if they had poor erlotinib compliance (self-reported data, validated with the family), withdrew consent, developed brain metastases, or became physically unfit.
Ethical approval was obtained from Research Ethics Committee of Tianjin Cancer Hospital. All participants and their families, who were interested in participating, signed a "permission to contact" form and were subsequently contacted by the research team (principal investigator (director), co-investigators (one deputy director, two attending doctors and four residents), and two research nurses) to assess eligibility (based on the data in the medical chart) and obtain consent.
When subsequent evaluation reported that the patient was unaware or partly aware of disease status, a caregiver was also recruited.
| Procedure
Assessment of the background socio-demographic characteristics and baseline anxiety/distress and QoL was performed by a brief 10-15 min interview by telephone or face-to-face before starting erlotinib treatment, as previously described (Fan et al., 2011; Tang et al., 2006) . Questions were asked about the disease of the patient to determine if they were aware of their disease and status. Patients were asked if they were aware of their diagnosis and prognosis separately. For those who reported being aware of their diagnosis/prognosis, they were asked to provide the name of the disease and whether it was curable or incurable. If the patient reported being unaware of their disease, no further question was asked. The family members and caregivers were interviewed separately. 
| Outcome variables
Psychological distress was measured using the HADS (Schofield, Beeney & Thompson, 2001) , which measures generalised anxiety and depression experienced during the past week. It uses two subscales:
anxiety (HADS-A) and depression (HADS-D) (Novack, Plumer & Smith, 1979; Schofield et al., 2001) . A cut-off of ≥8 was used to indicate at least mild distress on each subscale. In addition, a total HADS score (HADS-T) of ≥15 was used to indicate clinically significant distress (Novack et al., 1979; Schofield et al., 2001) . HADS has been extensively used in cancer patients (Biemar and Foti, 2013) . QoL was measured using the FACT-L scale (version 4). The FACT-L assesses physical wellbeing, social/family well-being, emotional well-being, functional wellbeing and lung-cancer-specific concerns. Higher scores indicate better QoL (Chen et al., 2013; Slevin, 1987) . Scale reliability was excellent (α = 0.92).
| Statistical analysis
According to the results of the interview, the patients were classified as unaware, partly aware and fully aware of their disease. Normally distributed variables are presented as mean ± SD. Because of the highly skewed distribution of the HADS and FACT-L scores, parametric analyses could not be performed. Results are presented as median (range). Change from baseline to 12 weeks in the HADS and FACT-L scores were analysed using the Kruskal-Wallis test followed by the Mann-Whitney post-hoc test. Associations of clinically significant emotional distress (HADS >15) with possibly associated variables (disease awareness, age and gender) were examined using multivariate analysis. All statistical analyses were conducted using sAs version 9.1 (SAS Institute, Cary, NY, USA). stAtA 9 (StataCorp LP, College Station, TX, USA) was used to calculate prevalence estimates. Twosided p < .05 were considered statistically significant.
| RESULTS
| Characteristics of the subjects
Between August 2013 and August 2015, 178 patients participated in the study. Of these patients, 154 had confirmed disease and received treatment (erlotinib) (Figure 1) . Finally, 137 patients were included in the QoL and HADS analyses. The baseline clinical characteristics are shown in Table 1 .
| HADS scores
Among all 137 participants, 63.5% (n = 87) were anxious (HADS-A score ≥8) and 71.5% (n = 98) were depressed (HADS-D score ≥8) (Table 2) . Overall, 75.2% of the participants (n = 103) were distressed (HADS-T score ≥15). Aware participants had a higher mean score for anxiety, depression and distress (p < .05). Mean scores for measures of anxiety and distress were significantly lower for participants >70 years old. Levels of distress were not significantly different across categories of the other socio-demographic variables. Table 3 shows the multivariate analysis associated with clinically significant distress. Unaware patients and those aged >70 years were more likely to suffer from clinically significant distress. The associations of clinically significant anxiety and depression were similar to those with clinically significant emotional distress.
| Multivariate analysis
| Distribution of the HADS-T and QoL
The distribution of the HADS-T scores of the 137 patients is presented in Figure 2 . The distribution was skewed towards lower scores (less distress) in unaware patients. Nevertheless, this group showed The mean baseline and 12 week QoL scores were different among the three treatment groups. The unaware group had better scores than the other groups in all FACT-L subscales, reaching statistical significance for social/family well-being (p = .032) and functional well-being (p = .042). Because unaware patients could not judge themselves in emotional well-being, the data was not analysed (Figure 3) . The fully and partly aware patients showed significant improvement in their total FACT-L and HADS scores (p < .05 for both covariate analyses in all scales). The improvement in HADS was more variable (p < .05).
Although variability was high, unaware patients had consistently significant improvements in HADS and QoL (Figure 3) . Of the 137 patients included in the analyses at baseline, 93.4% (n = 124) completed the questionnaire after 12 weeks.
| DISCUSSION
Many studies emphasised the importance of providing complete and truthful information regarding diagnosis and prognosis to each cancer patient regardless of their gender, age or educational level (Hari, Mark & Bharati, 2007; Masood, Beenish & Zubia, 2010) . In addition, on the point of view of the physician, in a study from Japan and another from Australia showed that 88% and 85%, respectively, of medical students prefer the communication of prognosis in a metastatic setting (Ohtsu, Kaneita & Ohida, 2009; Schofield et al., 2001) .
General conclusions about patient awareness of their cancer and its prognosis have been difficult to draw because of methodological limitations and diverse ethnic origin (Frédéric and Margaret 2013; Novack et al., 1979; Slevin, 1987 vulnerability and high levels of psychological distress after diagnosis. Stage IV lung cancer perceptions about treatment involve futility and inevitability of death (Akechi et al., 2006; Brown Johnson et al., 2014; Hopwood & Stephens, 2000) . Thus, full awareness of malignant disease, including a poor prognosis, may heighten the negative appraisal of lung cancer patients about their cancer (Chambers, Morris & Clutton, 2015; Rueda, Solà, Pascual & Subirana, 2011) . Irrespective of cultural origin, religion, ethics and educational level, the patients exhibit considerable degrees of fear and anxiety about cancer as an untreatable disease and of facing death (Leydon, Bynoe-Sutherland & Coleman, 2003; Sharf, Stelljes & Gordon, 2005) .
Results of the present study revealed that patients who were fully However, in the present study, there were no significant differences for age (Ajaj, Singh & Abdulla, 2001; Butow, Maclean & Dunn, 1997; Fitch, McAndrew & Harth, 2015) .
The present study has several strengths. This study is the first to investigate whether having full knowledge of the diagnosis and prognosis of the illness would affect erlotinib treatment among patients with advanced NSCLC. In addition, the follow-up measurement indicating sustainability of the intervention program is a novelty in this field.
Being aware of the real disease status could be beneficial to patients, at least in part, by heightening the feelings of threat that the cancer patient cannot cope with. Considering cultural and popular belief, this study strongly supports the view that this group of patients should not be informed or that a more gradual approach in disclosing the real disease status should be taken to ensure that the patients do not struggle with psychological conflicts. In particular, patients who are aware of their disease status may experience fear and rejection, which are commonly accompanied by a lower prevalence of emotional distress, leading to a compromised QoL and poor mental well-being (Brown Johnson et al., 2014; Walker et al., 2013) .
Nevertheless, the present study has several limitations. The first limitation concerns the patient sample; the number of subjects in each group was not equal and a follow-up cohort study could be needed.
The second limitation concerns the Chinese healthcare system, which may differ from that of other countries and may limit the generalisability of this study. The last, caregivers were asked to provide some information instead of the patient, which could introduce some bias, but considering that the intervention was designed for inpatients and home-based settings, the results of the study may still be applicable to diverse settings.
Despite these limitations, this study reveals that patients who are aware of terminal status of their illness process their cancer experience towards a sense of acceptance. On the other hand, being unaware of the diagnosis and prognosis may limit psychological damage, leading to better HADS and QoL. Nevertheless, these results are only applicable, for now, to patients with first-line erlotinib therapy for EGFR mutation-positive advanced NSCLC.
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